Small interfering RNA-mediated suppression of serum response factor, E2-promotor binding factor and survivin in non-small cell lung cancer cell lines by non-viral transfection

European Journal of Cardio-thoracic Surgery

Volumn 43, Issue 3, 2013, Pages 628-634

  Walker, Tobias ^a   Nolte, Andrea ^a   Steger, Volker ^a   Makowiecki, Christina ^a   Mustafi, Migdat ^a   Friedel, Godehard ^b   Schlensak, Christian ^a   Wendel, Hans Peter ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Schillerhöhe Hospital   (Germany)

Author keywords

E2F1; Lung cancer; siRNA; SRF; Survivin

Indexed keywords

MESSENGER RNA; SERUM RESPONSE FACTOR; SMALL INTERFERING RNA; SURVIVIN; TRANSCRIPTION FACTOR E2F1;

ARTICLE; CANCER CELL; CELL COUNT; CELL CULTURE; CELL DIVISION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; E2F1 TRANSCRIPTION FACTOR; GENE SILENCING; GENETIC THERAPY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; RNA, MESSENGER; RNA, SMALL INTERFERING; SERUM RESPONSE FACTOR; TRANSFECTION;

EID: 84873676776     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezs337     Document Type: Article

References (17)

1. Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 2011;13:309-19.
2. Wang X, Chen Y, Ren J, Qu X. Small interfering RNA for effective cancer therapies. Mini Rev Med Chem 2011;11:114-24.
3. Walker T, Muller I, Raabe C, Nohe B, Zanke C, Ziemer G et al. Effective silencing of adhesion molecules on venous endothelial cells for protection of venous bypass grafts. Eur J Cardiothorac Surg 2011;40: 1241-7.
4. Walker T, Wendel HP, Raabe C, Wiechnik P, Spranger L, Heidenreich O et al. Graft protection in bypass surgery: siRNA-mediated silencing of adhesion molecules. Oligonucleotides 2009;19:15-21.
5. Werth D, Grassi G, Konjer N, Dapas B, Farra R, Giansante C et al. Proliferation of human primary vascular smooth muscle cells depends on serum response factor. Eur J Cell Biol 2010;89:216-24.
6. Putzer BM. E2F1 death pathways as targets for cancer therapy. J Cell Mol Med 2007;11:239-51.
7. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008;8:61-70.
8. Brandt DT, Xu J, Steinbeisser H, Grosse R. Regulation of myocardinrelated transcriptional coactivators through cofactor interactions in differentiation and cancer. Cell Cycle 2009;8:2523-27.
9. Burley SK, Kamada K. Transcription factor complexes. Curr Opin Struct Biol 2002;12:225-30.
10. Emmrich S, Putzer BM. Checks and balances: E2F-microRNA crosstalk in cancer control. Cell Cycle 2010;9:2555-67.
11. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
12. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumour-associated angiogenesis. Clin Cancer Res 2003;9:2683-92.
13. Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE, Morris JC. Impacting tumour cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer 2011;10:35.
14. Escuin D, Rosell R. The anti-apoptosis survivin gene and its role in human cancer: an overview. Clin Lung Cancer 1999;1:138-43.
15. Kren L, Brazdil J, Hermanova M, Goncharuk VN, Kallakury BV, Kaur P et al. Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immuno histochem Mol Morphol 2004;12:44-49.
16. Nolte A, Raabe C, Walker T, Simon P, Ziemer G, Wendel HP. Optimized basic conditions are essential for successful siRNA transfection into primary endothelial cells. Oligonucleotides 2009;19:141-50.
17. Paduano F, Villa R, Pennati M, Folini M, Binda M, Daidone MG et al. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther 2006;5:179-86.